Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EBITDA (2016 - 2025)

Historic EBITDA for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $3.0 million.

  • Ptc Therapeutics' EBITDA rose 10553.29% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $775.9 million, marking a year-over-year increase of 67747.04%. This contributed to the annual value of -$302.6 million for FY2024, which is 3115.62% up from last year.
  • Per Ptc Therapeutics' latest filing, its EBITDA stood at $3.0 million for Q3 2025, which was up 10553.29% from -$35.0 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year EBITDA high stood at $970.2 million for Q1 2025, and its period low was -$209.5 million during Q2 2023.
  • Over the past 5 years, Ptc Therapeutics' median EBITDA value was -$86.5 million (recorded in 2022), while the average stood at -$32.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 289018.9% in 2024, then skyrocketed by 223456.76% in 2025.
  • Ptc Therapeutics' EBITDA (Quarter) stood at -$84.7 million in 2021, then tumbled by 136.45% to -$200.3 million in 2022, then surged by 102.91% to $5.8 million in 2023, then crashed by 2890.19% to -$162.4 million in 2024, then skyrocketed by 101.86% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, -$35.0 million for Q2 2025, and $970.2 million during Q1 2025.